Rebecca M. Ricklis

838 total citations
12 papers, 629 citations indexed

About

Rebecca M. Ricklis is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Rebecca M. Ricklis has authored 12 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Hematology and 4 papers in Genetics. Recurrent topics in Rebecca M. Ricklis's work include Acute Myeloid Leukemia Research (6 papers), Acute Lymphoblastic Leukemia research (4 papers) and Cancer therapeutics and mechanisms (2 papers). Rebecca M. Ricklis is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Acute Lymphoblastic Leukemia research (4 papers) and Cancer therapeutics and mechanisms (2 papers). Rebecca M. Ricklis collaborates with scholars based in United States, Denmark and Israel. Rebecca M. Ricklis's co-authors include Benjamin Enav, Nina S. Levy, Meira Melamed‐Frank, Andrew P. Levy, Orit Lache, Samuel R. Denmeade, Dina Rosen, John T. Isaacs, Lori J. Sokoll and Debra J. Bruzek and has published in prestigious journals such as Blood, British Journal of Haematology and Leukemia.

In The Last Decade

Rebecca M. Ricklis

12 papers receiving 615 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rebecca M. Ricklis United States 9 252 195 118 101 94 12 629
Deborah A. Granger United States 9 724 2.9× 99 0.5× 63 0.5× 54 0.5× 31 0.3× 11 941
Emanuela Ferru Italy 13 248 1.0× 98 0.5× 158 1.3× 163 1.6× 135 1.4× 16 771
Jina Wang China 15 613 2.4× 73 0.4× 64 0.5× 80 0.8× 27 0.3× 33 1.0k
Lurong Lian United States 17 305 1.2× 180 0.9× 71 0.6× 211 2.1× 21 0.2× 24 753
Madan G. Luthra United States 13 520 2.1× 79 0.4× 181 1.5× 137 1.4× 55 0.6× 20 967
Eric Chan China 13 241 1.0× 87 0.4× 79 0.7× 84 0.8× 11 0.1× 21 729
Cecilia Evangelisti Italy 18 466 1.8× 105 0.5× 32 0.3× 222 2.2× 22 0.2× 28 928
Gitte Hoffmann Bruun Denmark 14 528 2.1× 41 0.2× 24 0.2× 54 0.5× 101 1.1× 17 862
Hisaichi Fujii Japan 20 355 1.4× 69 0.4× 97 0.8× 178 1.8× 337 3.6× 53 952
Prince George United States 6 945 3.8× 76 0.4× 25 0.2× 231 2.3× 33 0.4× 9 1.2k

Countries citing papers authored by Rebecca M. Ricklis

Since Specialization
Citations

This map shows the geographic impact of Rebecca M. Ricklis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca M. Ricklis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca M. Ricklis more than expected).

Fields of papers citing papers by Rebecca M. Ricklis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca M. Ricklis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca M. Ricklis. The network helps show where Rebecca M. Ricklis may publish in the future.

Co-authorship network of co-authors of Rebecca M. Ricklis

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca M. Ricklis. A scholar is included among the top collaborators of Rebecca M. Ricklis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca M. Ricklis. Rebecca M. Ricklis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Zeidan, Amer M., Rebecca M. Ricklis, Hetty E. Carraway, et al.. (2012). Phase 1 dose‐escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. British Journal of Haematology. 158(2). 198–207. 6 indexed citations
2.
Gore, Lia, Rebecca M. Ricklis, Jessica Boklan, et al.. (2012). Phase I dose‐escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Pediatric Blood & Cancer. 59(7). 1252–1258. 8 indexed citations
3.
Lancet, Jeffrey E., Farhad Ravandi, Rebecca M. Ricklis, et al.. (2011). A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 25(12). 1808–1814. 42 indexed citations
4.
Zhao, Ming, Linping Xu, Rebecca M. Ricklis, et al.. (2009). A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 52(1). 122–128. 11 indexed citations
5.
Karp, Judith E., Rebecca M. Ricklis, Kumudha Balakrishnan, et al.. (2007). A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 110(6). 1762–1769. 59 indexed citations
6.
7.
Aggarwal, Saurabh, Rebecca M. Ricklis, Simon A. Williams, & Samuel R. Denmeade. (2006). Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human. The Prostate. 66(9). 903–910. 34 indexed citations
8.
Karp, Judith E., Rebecca M. Ricklis, Jacqueline M. Greer, Janet Briel, & Mark J. Levis. (2006). Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage.. Blood. 108(11). 1963–1963. 2 indexed citations
9.
Rosen, Dina, Rebecca M. Ricklis, Craig A. Dionne, et al.. (2005). Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)‐activated thapsigargin prodrug. The Prostate. 66(4). 358–368. 43 indexed citations
10.
Rosen, Dina, Rebecca M. Ricklis, Ulrich Reineke, et al.. (2004). Screening a combinatorial peptide library to develop a human glandular kallikrein 2–activated prodrug as targeted therapy for prostate cancer. Molecular Cancer Therapeutics. 3(11). 1439–1450. 32 indexed citations
11.
Denmeade, Samuel R., Lori J. Sokoll, Susan L. Dalrymple, et al.. (2003). Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. The Prostate. 54(4). 249–257. 111 indexed citations
12.
Melamed‐Frank, Meira, Orit Lache, Benjamin Enav, et al.. (2001). Structure-function analysis of the antioxidant properties of haptoglobin. Blood. 98(13). 3693–3698. 277 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deborah A. Granger Breakdown of academic impact, for papers by Emanuela Ferru Breakdown of academic impact, for papers by Jina Wang Breakdown of academic impact, for papers by Lurong Lian Breakdown of academic impact, for papers by Madan G. Luthra Breakdown of academic impact, for papers by Eric Chan Breakdown of academic impact, for papers by Cecilia Evangelisti Breakdown of academic impact, for papers by Gitte Hoffmann Bruun Breakdown of academic impact, for papers by Hisaichi Fujii Breakdown of academic impact, for papers by Prince George
Rankless by CCL
2026